97 related articles for article (PubMed ID: 10612426)
1. Estrogen receptor cofactors expression in breast and endometrial human cancer cells.
Thenot S; Charpin M; Bonnet S; Cavailles V
Mol Cell Endocrinol; 1999 Oct; 156(1-2):85-93. PubMed ID: 10612426
[TBL] [Abstract][Full Text] [Related]
2. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.
Kurebayashi J; Otsuki T; Kunisue H; Tanaka K; Yamamoto S; Sonoo H
Clin Cancer Res; 2000 Feb; 6(2):512-8. PubMed ID: 10690532
[TBL] [Abstract][Full Text] [Related]
3. Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.
Chan CM; Lykkesfeldt AE; Parker MG; Dowsett M
Clin Cancer Res; 1999 Nov; 5(11):3460-7. PubMed ID: 10589759
[TBL] [Abstract][Full Text] [Related]
4. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
5. Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins.
Schaufele F
Mol Endocrinol; 1999 Jun; 13(6):935-45. PubMed ID: 10379892
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M
Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853
[TBL] [Abstract][Full Text] [Related]
7. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells.
Philips A; Teyssier C; Galtier F; Rivier-Covas C; Rey JM; Rochefort H; Chalbos D
Mol Endocrinol; 1998 Jul; 12(7):973-85. PubMed ID: 9658402
[TBL] [Abstract][Full Text] [Related]
8. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
[TBL] [Abstract][Full Text] [Related]
9. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.
Uchikawa J; Shiozawa T; Shih HC; Miyamoto T; Feng YZ; Kashima H; Oka K; Konishi I
Cancer; 2003 Nov; 98(10):2207-13. PubMed ID: 14601091
[TBL] [Abstract][Full Text] [Related]
10. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative reverse transcription-polymerase chain reaction to evaluate the expression patterns of genes involved in the oestrogen pathway.
Rey JM; Pujol P; Callier P; Cavailles V; Freiss G; Maudelonde T; Brouillet JP
J Mol Endocrinol; 2000 Jun; 24(3):433-40. PubMed ID: 10828836
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells.
Bhat KP; Pezzuto JM
Cancer Res; 2001 Aug; 61(16):6137-44. PubMed ID: 11507064
[TBL] [Abstract][Full Text] [Related]
14. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
[TBL] [Abstract][Full Text] [Related]
15. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Shah YM; Rowan BG
Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
[TBL] [Abstract][Full Text] [Related]
16. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3.
Magklara A; Brown TJ; Diamandis EP
Int J Cancer; 2002 Aug; 100(5):507-14. PubMed ID: 12124798
[TBL] [Abstract][Full Text] [Related]
17. Oxidative and reductive pathways of estrogens in hormone responsive and non-responsive human breast cancer cells in vitro.
Castagnetta LA; Granata OM; Farruggio R; Cannella S; Montesanti A; Oliveri G; Sorci C; Mesiti M; Carruba G
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):367-74. PubMed ID: 7626482
[TBL] [Abstract][Full Text] [Related]
18. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
19. Expression of nuclear receptors and cofactors in human endometrium and myometrium.
Vienonen A; Miettinen S; Bläuer M; Martikainen PM; Tomás E; Heinonen PK; Ylikomi T
J Soc Gynecol Investig; 2004 Feb; 11(2):104-12. PubMed ID: 14980312
[TBL] [Abstract][Full Text] [Related]
20. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
